Project 1: Steroid Hormone Action in Uterine Leiomyoma
项目 1:类固醇激素在子宫平滑肌瘤中的作用
基本信息
- 批准号:8099638
- 负责人:
- 金额:$ 30.59万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-07-01 至 2014-06-30
- 项目状态:已结题
- 来源:
- 关键词:AKT Signaling PathwayAKT inhibitionAffectAgonistAnimal ModelApoptosisAttenuatedBCL2L11 geneBinding SitesBiological ModelsBiologyCell Cycle ArrestCell DeathCell NucleusCell ProliferationCell SurvivalCellsCessation of lifeChemicalsCytoplasmDataEP300 geneEstrogensEventExcisionFGR geneFigs - dietaryFunctional disorderGenesGenomicsGrowthHemorrhageHormonesHumanHysterectomyImmunocompromised HostIn VitroInfertilityInstructionKidneyLeiomyomaLigandsLightMediatingMolecularMorbidity - disease rateMusMyometrialNecrosisPI3K/AKTPathway interactionsPelvisPhosphorylationProcessProgesteroneProgesterone ReceptorsProgestinsProto-Oncogene Proteins c-aktRU-5020Research PersonnelRoleSH3 DomainsSignal PathwaySignal TransductionSmooth Muscle TumorTestingTissue GraftsTissuesTransactivationTranslatingUnited StatesUterine FibroidsUterusWomanattenuationbasecapsuleeffective therapyefficacy testingin vivoin vivo Modelinhibitor/antagonistmembermyometriumnon-genomicprogramspromoterreceptorreproductiveresponsesteroid hormonetranscription factor
项目摘要
Uterine leiomyomas occur in approximately 77% of all women in the United States and can cause severe morbidity and
infertility. To date, there is no effective treatment for leiomyomas besides hysterectomies. In this application, we hope
to better understand the biology behind uterine leiomyoma growth at the cellular and molecular level. Specifically,
there is evidence that the hormone progesterone causes leiomyomas to grow and once we understand how progesterone,
through its receptor, PR, promotes leiomyoma growth, we can begin to study ways to inhibit this process. We have
gathered evidence that progesterone can activate the AKT pathway which is a pathway that is involved in cell
proliferation and survival. In addition, we have found that progesterone, through PR, can attenuate the action of a
transcription factor, FOXOI, which is a member ofthe AKT pathway as well as a molecule that inhibits cell
proliferation and promotes cell death. In light of this, we have gathered preliminary evidence testing the efficacy of a
chemical compound, an AKT inhibitor for treating leiomyomas in an animal model. We observe that the AKT inhibitor
causes significant tissue necrosis in leiomyomas that have been grown in immunocompromised mice. In this proposal,
we hypothesize that progesterone can act at both non-genomic (signaling events) as well as genomic (at the gene) levels
to promote leiomyoma growth. It does this by targeting the AKT signaling pathway and the downstream effector,
FOXOI. Thus, inhibition of this pathway should provide a means of inhibiting leiomyoma growth and promoting
tissue death. To test this hypothesis, we propose three aims. Specific aim 1 will investigate the elucidating the
mechanisms that are involved in PR attenuation of FOXOI action on a gene called BM, that is involved in apoptosis
(cell death). Specific aim 2 will explore how progesterone activates the AKT pathway and what the consquence of
inhibiting this pathway would be on cell proliferation. Specific aim 3 investigates the efficacy of the AKT inhibitor in
inducing apoptosis in leiomyoma cells as well as human leiomyoma tissues that are growing in immunocompromised
mice.
RELEVANCE (See instructions):
Millions of women in the US are affected by symptomatic uterine leiomyomata causing significant morbidity.
The studies in this project explore an important signaling pathway, PI3K/AKT/F0X01, that is activated by
progesterone and associated with cell proliferation and survival. This study will provide a potential
mechanism of action of PR in promoting growth of leiomyomas and translate these data into a potential
treatment nf leiomyomas. ;
PROJEeT/
在美国,大约77%的妇女发生子宫平滑肌瘤,并可导致严重的发病率和
不孕迄今为止,除了子宫肌瘤切除术外,没有有效的治疗方法。在这个应用程序中,我们希望
以更好地了解子宫肌瘤生长背后的细胞和分子水平的生物学。具体地说,
有证据表明孕酮激素导致平滑肌瘤生长,一旦我们了解了孕酮,
通过其受体PR促进平滑肌瘤生长,我们可以开始研究抑制这一过程的方法。我们有
收集的证据表明,孕酮可以激活AKT途径,这是一种参与细胞凋亡的途径。
增殖和生存。此外,我们发现黄体酮通过PR可以减弱A的作用。
转录因子FOXOI是AKT通路的成员,也是抑制细胞增殖的分子。
增殖并促进细胞死亡。有鉴于此,我们已经收集了初步证据,
化合物,AKT抑制剂,用于治疗动物模型中的平滑肌瘤。我们观察到AKT抑制剂
导致免疫功能低下小鼠体内生长的平滑肌瘤显著的组织坏死。在这项提案中,
我们假设孕酮可以在非基因组(信号事件)和基因组(基因)水平上起作用。
促进平滑肌瘤生长。它通过靶向AKT信号通路和下游效应子来实现这一点,
福克斯。因此,抑制该途径应该提供抑制平滑肌瘤生长和促进平滑肌瘤生长的手段。
组织死亡为了验证这一假设,我们提出了三个目标。具体目标1将研究阐明
参与PR减弱FOXOI作用于BM基因的机制,BM参与细胞凋亡
(cell死亡)。具体目标2将探讨孕激素如何激活AKT通路,以及
抑制这一途径将影响细胞增殖。具体目标3研究AKT抑制剂在以下中的功效:
诱导平滑肌瘤细胞以及在免疫缺陷中生长的人平滑肌瘤组织的凋亡,
小鼠
相关性(参见说明):
在美国,数百万妇女受到有症状的子宫平滑肌瘤的影响,导致严重的发病率。
本项目中的研究探索了一个重要的信号通路,PI 3 K/AKT/F0 X 01,其被激活,
孕酮和与细胞增殖和存活相关。这项研究将提供一个潜在的
PR促进平滑肌瘤生长的作用机制,并将这些数据转化为潜在的
治疗子宫肌瘤。;
项目/
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Serdar E. Bulun其他文献
グラビア・目で見る遺伝子異常と婦人科内分泌疾患―早発卵巣不全―
凹印/可见基因异常与妇科内分泌疾病 - 卵巢早衰 -
- DOI:
- 发表时间:
2017 - 期刊:
- 影响因子:0
- 作者:
Masanori Ono;Tetsuo Maruyama;Mamoru Tanaka;Daisuke Aoki;Serdar E. Bulun;河村和弘・佐藤可野・鈴木直 - 通讯作者:
河村和弘・佐藤可野・鈴木直
STEROYL-CoA DESATURASE INHIBITION IS ASSOCIATED WITH DECREASED UTERINE LEIOMYOMA CELL VIABILITY
- DOI:
10.1016/j.fertnstert.2023.08.600 - 发表时间:
2023-10-01 - 期刊:
- 影响因子:
- 作者:
Allison S. Komorowski;Azna Zuberi;John S. Coon V;Melania Anton;Serdar E. Bulun;Ping Yin - 通讯作者:
Ping Yin
Therapeutic targeting of the tryptophan-kynurenine-aryl hydrocarbon receptor pathway with apigenin in MED12-mutant leiomyoma cells
芹菜素对 MED12 突变型平滑肌瘤细胞中色氨酸-犬尿氨酸-芳烃受体通路的治疗靶向作用
- DOI:
10.1038/s41417-025-00881-0 - 发表时间:
2025-03-01 - 期刊:
- 影响因子:5.000
- 作者:
Takashi Iizuka;Azna Zuberi;Helen Wei;John S. Coon V;Melania Lidia Anton;Kadir Buyukcelebi;Mazhar Adli;Serdar E. Bulun;Ping Yin - 通讯作者:
Ping Yin
Role of WNT/CTNNB1 pathway in differentiation of human induced pluced pluripotent stem cells to endometrial stroma-like cells
WNT/CTNNB1通路在人诱导多能干细胞向子宫内膜基质样细胞分化中的作用
- DOI:
- 发表时间:
2018 - 期刊:
- 影响因子:0
- 作者:
Kaoru Miyazaki;Matthew T. Dyson;John S. Coon;Tetsuo Maruyama;Serdar E. Bulun - 通讯作者:
Serdar E. Bulun
Transcriptome analysis of endometrial stroma-like ofganoids differentiated from human induced pluripotent stem cells
人诱导多能干细胞分化的子宫内膜基质样细胞的转录组分析
- DOI:
- 发表时间:
2017 - 期刊:
- 影响因子:0
- 作者:
Kaoru Miyazaki ;Matthew T. Dyson ;John S. Coon;Maruyama T;Serdar E. Bulun - 通讯作者:
Serdar E. Bulun
Serdar E. Bulun的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Serdar E. Bulun', 18)}}的其他基金
Estrogen, Astrocyte Reactivity, and Sex Differences in Alzheimer's Disease
阿尔茨海默病中的雌激素、星形胶质细胞反应性和性别差异
- 批准号:
10662993 - 财政年份:2023
- 资助金额:
$ 30.59万 - 项目类别:
Environmental Pollutants and AHR pathway in Uterine Leiomyoma
环境污染物与子宫平滑肌瘤的 AHR 通路
- 批准号:
10567192 - 财政年份:2022
- 资助金额:
$ 30.59万 - 项目类别:
Epigenome, MED12 and Progesterone Action in Uterine Leiomyomas
表观基因组、MED12 和孕酮在子宫平滑肌瘤中的作用
- 批准号:
10396486 - 财政年份:2019
- 资助金额:
$ 30.59万 - 项目类别:
相似海外基金
Elucidating resistance to AKT inhibition in metastatic breast cancer
阐明转移性乳腺癌对 AKT 抑制的耐药性
- 批准号:
2440937 - 财政年份:2020
- 资助金额:
$ 30.59万 - 项目类别:
Studentship
The Risk of Novel AKT Inhibition on Lethal Neuroendocrine Prostate Cancer Development
新型 AKT 抑制对致死性神经内分泌前列腺癌发展的风险
- 批准号:
350042 - 财政年份:2015
- 资助金额:
$ 30.59万 - 项目类别:
Studentship Programs
Mechanistic studies of cancer cell adaptive response to PI3K/AKT inhibition
癌细胞对 PI3K/AKT 抑制的适应性反应的机制研究
- 批准号:
9272854 - 财政年份:2015
- 资助金额:
$ 30.59万 - 项目类别:
Targeting RAS signaling with CDK and AKT inhibition in pancreatic cancer
通过 CDK 和 AKT 抑制作用靶向胰腺癌中的 RAS 信号传导
- 批准号:
8581465 - 财政年份:2013
- 资助金额:
$ 30.59万 - 项目类别:
Targeting RAS signaling with CDK and AKT inhibition in pancreatic cancer
通过 CDK 和 AKT 抑制作用靶向胰腺癌中的 RAS 信号传导
- 批准号:
8692694 - 财政年份:2013
- 资助金额:
$ 30.59万 - 项目类别:














{{item.name}}会员




